Business Description
Cognition Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US19243B1026
Description
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 33.53 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -44.7 | |||||
3-Year EPS without NRI Growth Rate | -32.5 | |||||
3-Year FCF Growth Rate | -49.5 | |||||
Future 3-5Y EPS without NRI Growth Rate | -27.75 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 64.48 | |||||
9-Day RSI | 53.05 | |||||
14-Day RSI | 49.75 | |||||
6-1 Month Momentum % | -1.55 | |||||
12-1 Month Momentum % | 17.28 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4 | |||||
Quick Ratio | 4 | |||||
Cash Ratio | 3.65 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.6 | |||||
Shareholder Yield % | -22.63 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -94.36 | |||||
ROA % | -71.06 | |||||
ROIC % | -638.93 | |||||
ROC (Joel Greenblatt) % | -2986.28 | |||||
ROCE % | -90.3 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.65 | |||||
Price-to-Tangible-Book | 2.65 | |||||
EV-to-EBIT | -1.49 | |||||
EV-to-EBITDA | -1.5 | |||||
EV-to-FCF | -2.07 | |||||
Price-to-Net-Current-Asset-Value | 2.73 | |||||
Price-to-Net-Cash | 3.09 | |||||
Earnings Yield (Greenblatt) % | -67.11 | |||||
FCF Yield % | -27.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CGTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cognition Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -0.92 | ||
Beta | 0 | ||
Volatility % | 81.52 | ||
14-Day RSI | 49.75 | ||
14-Day ATR ($) | 0.171604 | ||
20-Day SMA ($) | 1.9265 | ||
12-1 Month Momentum % | 17.28 | ||
52-Week Range ($) | 0.9001 - 2.95 | ||
Shares Outstanding (Mil) | 40.06 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Cognition Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Cognition Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Cognition Therapeutics Inc Frequently Asked Questions
What is Cognition Therapeutics Inc(CGTX)'s stock price today?
The current price of CGTX is $1.91. The 52 week high of CGTX is $2.95 and 52 week low is $0.90.
When is next earnings date of Cognition Therapeutics Inc(CGTX)?
The next earnings date of Cognition Therapeutics Inc(CGTX) is 2024-08-08 Est..
Does Cognition Therapeutics Inc(CGTX) pay dividends? If so, how much?
Cognition Therapeutics Inc(CGTX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |